DURECT Corporation  

(Public, NASDAQ:DRRX)   Watch this stock  
Find more results for DRRX
1.29
-0.03 (-2.27%)
After Hours: 1.29 0.00 (0.00%)
Dec 7, 4:50PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.27 - 1.34
52 week 0.99 - 2.40
Open 1.30
Vol / Avg. 0.00/500,403.00
Mkt cap 181.52M
P/E     -
Div/yield     -
EPS -0.24
Shares 138.58M
Beta 1.31
Inst. own 49%
Feb 27, 2017
Q4 2016 DURECT Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 15, 2016
DURECT Corp at Stifel Healthcare Conference
Oct 31, 2016
Q3 2016 DURECT Corp Earnings Call
Oct 31, 2016
Q3 2016 DURECT Corp Earnings Release
Sep 12, 2016
DURECT Corp at Rodman & Renshaw Global Investment Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -235.96% -118.51%
Operating margin -221.35% -108.05%
EBITD margin - -105.83%
Return on average assets -75.32% -46.80%
Return on average equity -220.68% -135.71%
Employees 106 -
CDP Score - -

Address

10240 Bubb Rd
CUPERTINO, CA 95014-4166
United States - Map
+1-408-7771417 (Phone)
+1-408-7773577 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.

Officers and directors

Felix D Theeuwes Chairman, Chief Scientific Officer
Age: 78
Bio & Compensation  - Reuters
James E. Brown DVM President, Chief Executive Officer and Director
Age: 58
Bio & Compensation  - Reuters
Matthew J. Hogan Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Judy R. Joice Senior Vice President - Operations and Corporate Quality Assurance
Age: 58
Bio & Compensation  - Reuters
David R. Hoffmann Lead Independent Director
Age: 70
Bio & Compensation  - Reuters
Simon X. Benito Independent Director
Age: 70
Bio & Compensation  - Reuters
Terrence F. Blaschke M.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Armand P. Neukermans Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Jon S Saxe Independent Director
Age: 79
Bio & Compensation  - Reuters